Molecular diagnosis of HAV along with anti-HAV IgG avidity measurement are helpful in case of positive IgM where laboratory evidence of acute hepatitis is absent and there is no epidemiologic link ...

IgY has greater binding avidity to target antigens than mammalian IgGs; IgY directed against conserved mammalian proteins is easier to produce than IgG because of the evolutionary distance between ...

We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a ...

Avidity Biosciences, Inc.'s innovative AOC platform and promising clinical programs make it a high-risk, high-reward ...

Avidity Biosciences, Inc.’s RNA share price has surged by 11.33%, which has investors questioning if this is right time to sell.

Just a few weeks after Avidity Biosciences made a stir with new data on its experimental therapy for Duchenne muscular dystrophy, the biotech has closed a public offering that raised an impressive ...

Avidity Biosciences (RNA) announced the completion of enrollment in the biomarker cohort in the Phase 1/2 Fortitude clinical trial of ...

Avidity Biosciences, Inc. (RNA) shares soared 11.3% in the last trading session to close at $29.77. The move was backed by solid volume with far more shares changing hands than in a normal session.

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has received a consensus rating of “Buy” from the thirteen research firms that are covering the company, MarketBeat.com reports. Thirteen ...

Avidity Biosciences, Inc. (NASDAQ:RNA), a biotechnology company specializing in precision medicine for rare diseases with a market capitalization of $3.51 billion, has been making significant ...

Avidity Biosciences’ Phase I/II trial of ribonucleic acid (RNA) therapy, del-zota, has increased dystrophin in patients with Duchenne muscular dystrophy (DMD). Results from the company’s ...

Molecular detection of HAV and anti-HAV IgG avidity testing are indicated to define protracted or relapsing forms of HAV infection or to confirm the etiology of a fulminant hepatitis. These ...